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Desmopressin is used to treat primary nocturnal enuresis in children. Over the years,
various formulations of desmopressin were commercialized of which the sublingual melt
tablet is preferred in the pediatric population, despite the lack of full PK studies in this
population. A full PK study was performed in growing conventional piglets to evaluate
if this juvenile animal model can provide supplementary information to complement
the information gap in the pediatric population. A desmopressin sublingual melt tablet
(120 µg) was administered to 32 male piglets aged 8 days, 4 weeks, 7 weeks, and
6 months (each group n = 8). Population PK (pop-PK) analysis was performed to
derive the PK parameters, the between- and within-subject variabilities and the effects of
covariates. Desmopressin demonstrated two-compartmental PK, with a dual, sequential
absorption process, and linear elimination. Body weight was the only significant covariate
on clearance and on apparent volume of distribution of the central compartment. In
human pediatric trials, no double peak in the absorption phase was observed in the
plasma concentration-time curves, possibly due to the sparse sampling strategy applied
in those pediatric studies. Therefore, it is recommended to perform additional studies,
based on the sampling protocol applied in the current study.
Keywords: piglet, animal model, pharmacokinetics, desmopressin, pediatric
Abbreviations: ADD, Additive residual error; AIC, Akaike’s information criteria; Bio, Fraction passing through depot 1;
BSA, Body surface area; BW, Body weight; CL/F, Apparent total body clearance; Cmax, Maximum plasma concentration;
CN, Condition number; Cobs, Observed concentrations; CV, Coefficient of variation; CWRES, Conditional weighted
residuals; D1, Duration of the zero-order input; EBE, Empirical Bayes estimates; EMA, European medicine agency; F,
Absolute oral bioavailability; FDA, Food and drug administration; IIV, Inter-individual variability; IPRED, Individual
predicted concentrations; Ka1, First-order absorption rate constant; Ka2, First-order absorption rate constant; LOQ,
Limit of quantification; OFV, Objection function value; PD, Pharmacodynamic; PNE, Primary nocturnal enuresis; PK,
Pharmacokinetic; PRED, Population predicted concentrations; Pop-PK, Population pharmacokinetic; Q/F, Apparent
intercompartmental flow; RSE, Relative standard error; SE, Standard error; Tlag, Lag time; V1/F, Apparent volume of
distribution (central); V2, Vasopressin 2; V2/F, Apparent volume of distribution (peripheral); VPC, Visual predictive check;
WRES, Weighted residuals.
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INTRODUCTION
Pediatric non-clinical and clinical studies are pivotal to
investigate inter alia age-dependent dosing schedules and age-
appropriate formulations. In order to stimulate the industry to
perform such pediatric clinical trials, the FDA (Food and Drug
Administration) and EMA (European Medicines Agency) issued
several regulations, such as the US Best Pharmaceuticals for
Children Act (2002), Pediatric Research Equity Act (2003) and
the Pediatric Regulation (2006). Despite the increased regulatory
efforts, there is still a lack of clinical trials in children, and
consequently a lack of medicines labeled for children (±50% of
the drugs are prescribed off-label).
Desmopressin (1-desamino-8-D-arginine vasopressin,
Figure 1) has an antidiuretic effect through binding on the
vasopressin 2 (V2) receptors of the kidney collecting ducts. It
was initially developed for the indication of central diabetes
insipidus in adults, but was subsequently used to treat primary
nocturnal enuresis (PNE) in children (Cobb et al., 1978; Rittig
et al., 1989; Glazener and Evans, 2002). Over more than 30
years, two oral [tablet (1987) and lyophilisate (2005)] and one
nasal formulation [spray (1972)] have been developed to reduce
PNE in children. In 2007, the use of intranasal formulations
was no longer approved for treating PNE in children in the
USA and most of the European countries, because of reported
cases of severe hyponatremia and seizures. Therefore, a switch
to oral formulations was required, despite the limited number
of data on the PK of oral desmopressin in children, the lack
of bioequivalence studies between the tablet and the oral
lyophilisate, and the lack of availability of size-dependent dosing
regimens in the pediatric population. Osterberg et al. (2006)
performed a pharmacokinetic (PK)/pharmacodynamic (PD)
study (oral lyophilisate, 30, 60, 120, 360, or 480 µg) in 84
enuretic children aged 6–12 years and applied a sparse sampling
protocol (2 to 3 blood samples/child). Also De Bruyne et al.
(2014) applied a sparse sampling protocol after administration
of conventional tablets (200 µg) and oral lyophilisates (120 µg)
containing desmopressin to 23 children (5–18 years) suffering
from monosymptomatic nocturnal enuresis. Blood was sampled
at 1, 2, and 6 h post administration. The full PK profiles were
obtained through pop-PK simulation (Michelet et al., 2016), but
FIGURE 1 | Structure of vasopressin (left) and desmopressin (right). Structural differences are marked (black circle).
likely do not capture all characteristics of desmopressin’s PK,
since the original studies applied a sparse sampling protocol.
It is in this respect, that trials using pediatric animal models,
such as the conventional piglet, might provide supplementary
information to complement the information gap since full PK
studies can be performed.
The overall aim of the present study was to evaluate whether
the conventional piglet is a potentially relevant animal model
for PK studies of desmopressin. The objective was to adequately
describe the desmopressin plasma concentration-time profiles
in piglets of 8 days, 4 weeks, 7 weeks, and 6 months, using
non-linear mixed effects modeling (NLME). These age groups
correspond to the main age categories of the human pediatric
population, namely neonate, infant, child, and adolescent (Gad,
2007; Gasthuys et al., 2016). The estimated values of the primary
PK parameters correlated with the values obtained in children,
also obtained using pop-PK analysis.
MATERIALS AND METHODS
Animals
The current study was approved by the ethical committee of
the Faculties of Veterinary Medicine and Bioscience Engineering
of Ghent University (EC2014/184). Care and use of animals
was in full compliance with the national (Belgian Royal Decree,
2013) and European legislation (Anonymous, 2010). A total of
32 stress-resistant male piglets (Landrace × large white, Seghers
Hybrid R©, Wuustwezel, Belgium) aged 8 days (n = 8, 2.01 ±
0.43 kg), 4 weeks (n = 8, 10.0 ± 1.69 kg), 7 weeks (n = 8, 13.9
± 2.74 kg), and 6 months (n = 8, 112.88 ± 9.11 kg) were used.
The animals were group housed in rescue decks (8 days) (0.9
× 1.40m, Provimi, Rotterdam, The Netherlands) and standard
pig stables (4 and 7 weeks, 6 months) (2.30 × 2.40m), and
had ad libitum access to feed (8 days: RescueMilk R©, Provimi; 4
and 7 weeks: Piggistart Opti R©, 6 months: Optivo Pro R©, Aveve,
Leuven, Belgium) and drinking water. Natural light was provided
by translucent windows and the stable temperature was 23.2 ±
0.56◦C. Higher temperatures were obtained in the rescue decks
through heating lamps. In all age groups, a double lumen catheter
was placed in the jugular vein according to Gasthuys et al.
(2017b). After surgery, the piglets were housed individually to
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avoid displacement of the catheters. During single housing, a
cotton towel was added to the decks and stables to mimic the
smell of the other piglets. During the experiments, the stables
were enriched with hanging chains, rubber toys and balls of
different sizes. The environmental enrichment was rotated daily.
Experimental Design
After one acclimatization day, a desmopressin oral lyophilisate
(Minirin R©Melt 120µg, kindly donated by Ferring, Copenhagen,
Denmark) was placed under the tongue of all the piglets.
Afterwards, the snout was closed during 30 s to ensure full
dissolution of the lyophilisate. The animals were deprived of milk
or feed 1 h before and 1.5 h after administration of desmopressin.
Venous blood samples (1mL) were collected through the distal
lumen of the catheter at 0 (just prior to administration), 5,
15, 30, 60, min and 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 h (post
administration). The samples were drawn into 9mL EDTA-
K3 collection tubes (Vacutest
R©, Piove di Sacco, Kima, Italy),
immediately kept on ice and centrifuged for 10min at 2,095 ×
g within 2 h after blood collection. The plasma was aliquoted,
frozen and stored at −80◦C until analysis (within 2 months).
The body surface of the piglets (8 days, 4 and 7 weeks)
was imaged using a four-slice helical CT-scanner (Lightspeed
QC/I, GE Medical systems, USA, New York). The CT-scans
were processed using VGStudioMax (Volume Graphics GmbH,
Heidelberg, Germany) and the body surface area (BSA) was
determined after visualization and selection of the body surface
in 3D (UGCT-Department of Physics and Astronomy, Ghent
University, Ghent, Belgium). The GFR was determined as the
clearance of the exogenous marker exo-iohexol (Gasthuys et al.,
2017a). After the experiment, euthanasia was performed by
administering an overdose of sodium pentobarbital (sodium
pentobarbital 20% R©, Kela, Belgium) through the proximal lumen
of the jugular catheter.
Desmopressin Analysis
Desmopressin plasma concentrations were determined at Aarhus
University Hospital (Aarhus, Denmark) using a validated
radioimmunoassay method as described by Emmeluth et al.
(1994) and Bie and Sandgaard (2000). A 1-desamino-8-D-
arginine vasopressin antibody (C990728, Biogenesis Ltd., Poole,
UK) was used at a final dilution of 1:125,000. The limit of
quantification (LOQ) was 4.2 pg/mL and the intra- and inter-
assay coefficient of variation was 7.9and 12.1%, respectively.
Pharmacokinetic Analysis
Software
The data and statistical analysis comply with the
recommendations on experimental design and analysis of
pharmacology (Curtis et al., 2015). Model development and
parameter estimation were performed by non-linear mixed effect
modeling using NONMEM R© version 7.3. (Icon Development
Solutions, Ellicott City, MD, USA).
Structural Model Development
The first-order conditional estimation method was used as the
estimation algorithm for all analyses. Plasma concentrations
below the LOQ were excluded from the analysis (4 pg/mL; n =
8%) and a logarithmic transformation of the remaining plasma
concentrations was performed. A one-compartmental model
with first-order absorption was chosen as the pop-PK basemodel,
analogous to the human pop-PK model development (Michelet
et al., 2016). Subsequently, based on a visual exploration
of the plasma concentration-time profiles obtained in the
growing piglets, a two-compartmental disposition model and
a dual-input were evaluated to describe the absorption of the
sublingual desmopressin lyophilisate. Various input functions
were additionally explored, for an optimal fitting of the observed
input profile. Structural model selection was guided by visual
inspection of goodness-of-fit plots, the objective function value
(OFV), Akaike’s information criterion (AIC) and the condition
number (CN). The models were chosen based on mechanistic
plausibility and smaller values of OFV and/or AIC and acceptable
CN.
Stochastic Model Development
The inter-individual variability (IIV) on clearance, volume of
distribution and the absorption parameters was assumed to be
log-normally distributed and was modeled using an exponential-
error model. The residual variability was described using the log-
transform both sides approach, which implies that the log of the
concentrations was modeled with an additive error (proportional
error model in the untransformed domain).
Covariate Model Development
Once the structural and error models were obtained, continuous
covariates were included using the stepwise covariate modeling
approach (forward selection followed by backward elimination).
Evaluated continuous covariates on central volume of
distribution (V1/F), apparent total body clearance (CL/F)
and absorption-related parameters were body weight (BW), BSA,
age and/or GFR. A covariate was considered significant when its
addition resulted in a decrease in OFV of more than 6.635 (χ²
test, df = 1, p< 0.01) and 10.828 (χ² test, df = 1, p< 0.001) after
forward inclusion and backward elimination of one covariate,
respectively.
Model Evaluation
The final model was evaluated based on diagnostic plots
of the individual (IPRED) and population (PRED) predicted
concentrations vs. the observed concentrations (Cobs), and time
after dose and PRED vs. the conditional weighted residuals
(CWRES). Evaluation of the diagnostic plots was based on visual
inspection of the plots for scatter and bias. The precision of the
parameter estimates was determined by calculating the relative
standard error (%RSE). The fixed- and random-effect estimates
with relative precision below 30% and 40–50%, respectively,
were considered as precisely estimated. A visual predictive check
(VPC) was performed to evaluate the predictive properties of
the final model based on 1,000 simulations of the original
dataset. The dependent variable Cobs (y-axis) was plotted against
the independent variable time after dosing (x-axis). The 50th
percentile (median) of the observed data and the simulated
predictions were presented. Moreover, the 5th (lower) and 95th
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(upper) percentiles were depicted, corresponding to an inter-
percentile range of 90% (= prediction interval). For all simulated
percentiles, the 95% confidence interval was also presented.
Secondary PK Parameters
The individual PK parameter estimates (= empirical Bayes
estimates, EBE) were computed during the estimation of the
final population parameters. The shrinkage was determined to
evaluate the quality of the EBE estimation, since the EBE tends
to shrink toward the population mean in case of non-informative
data. Shrinkage below 30% was considered acceptable. The
secondary parameters, namely AUC0→∞ and T½el were
calculated. The individual AUC values were determined by the
logarithmic trapezoidal method with extrapolation to infinity.
Statistical Analysis
The effect of age on AUC0→∞ and T½el was analyzed using one-
way analysis of variance after determination of normality and
variance homogeneity (SPSS 24, IBM, United States).
RESULTS
Population Characteristics
All piglets survived catheterization of the jugular vein without
any complications. All piglets received a desmopressin oral
lyophilisate under identical circumstances (deprived from food,
properly hydrated) and no general side effects were observed
during the experiment. The descriptive (mean± SD and median
[range]) characteristics are detailed in Table 1.
Pharmacokinetic Analysis
The model development path is described in Supplementary
Table 1. Figure 2 shows the plasma concentration-time profiles of
desmopressin. The best description of the plasma concentration-
time profiles of desmopressin in growing piglets was obtained
with a two-compartmental disposition model combined with a
dual input function for the absorption. A zero-order release into
a first depot followed by first-order absorption, and a first-order
release from a second depot after a lag time (Tlag), both into the
central compartment was chosen as the final model (Figure 3).
This model was required since many plasma concentration-time
profiles showed a 2nd peak in their profile implying that most
probably, a part of the dose has been ingested (1-Bio) rather
than directly absorbed through the buccal mucosae (Bio). The
main parameters included in the model were apparent total
body clearance (CL/F), apparent central and peripheral volume
of distribution (V1/F; V2/F), apparent intercompartmental flow
(Q/F), first-order absorption rate constants from the first and
second depot (Ka1; Ka2), the fraction of the dose split over
depot 1 and depot 2 (Bio), the lag time (Tlag) and duration
of the zero-order release (D1). Since no intravenous data were
obtained in piglets, the absolute oral bioavailability (F) could
not be estimated. The IIV of Q, Ka2 and Tlag could not be
estimated from the data, and was fixed to zero. The forward
inclusion and backward elimination of the covariate effect BW
on apparent clearance (CL/F) and apparent central volume of
distribution (V1/F) demonstrated a significant improvement of
the model (1OFV = 14.43 and 39.72, respectively). No other
covariates, including renal function and age, were found to be
significant for any of the parameters. The final pop-PK model
parameter estimates are presented in Table 2. Model diagnostic
plots presented in Figure 4 show the overall goodness-of-fit of
the final model. The IPRED (Figure 4A) vs. Cobs and PRED
(Figure 4B) vs. Cobs plots demonstrated no significant deviations
of the LOESS smoothed line from the line of unity, meaning
that appropriate structural models could be fitted for most
individuals and no major bias in the population components of
the model were found. The scatter plot of the CWRES vs. time
(Figure 4C) showed a symmetric distribution of the weighted
residuals around zero across the entire range of time after dosing,
implying that no major bias was observed. The scatter plot of
the CWRES vs. PRED (Figure 4D) showed positive WRES in
the lowest PRED, indicating a slight overprediction of the lowest
concentration values. The %RSE of the fixed- and random-effect
parameters were regarded acceptable [even though for V2/F, it
was just above 30% (31.4%)]. Most of the observations are within
the 90% prediction interval of the VPC (Figure 5) indicating that
the model could reliably predict the observations indicative of a
good performance of the final model.
The individual primary PK parameters were obtained directly
from the model, through the posthoc step (Bayesian feedback
step). The shrinkage of the primary parameters was acceptable
(Table 2). The shrinkage of V2/F was above 30%, but since the
shrinkage applies to the complete dataset, the values were still
used to calculate the VSS. The values for the secondary PK
parameters, AUC and T½ are depicted in Table 3. No significant
differences in AUC and T½ (p < 0.05) between the 4- and
7-week-old piglets were observed. A significant difference in
TABLE 1 | Descriptive characteristics of the piglet study population.
Characteristic 8 days 4 weeks 7 weeks 6 months
N◦ of piglets 8 8 8 8
BW (kg) Mean Median 2.01 ± 0.43
2.21 [1.54–2.64]
10.0 ± 1.69
10.0 [7.0–12.0]
15.8 ± 1.98
15.0 [14.0–19.0]
112.9 ± 9.11
113.6 [100.0–124.0]
BSA (m²) Mean Median 0.16 ± 0.02
0.17 [0.13–0.19]
0.46 ± 0.05
0.46 [0.36–0.52]
0.59 ± 0.08
0.63 [0.60–0.73]
2.42 ± 0.13
2.43 [2.23–2.58]
GFR (mL/min/m²) Mean Median 40.8 ± 8.62
40.6 [24.5–50.5]
67.4 ± 11.54
66.2 [54.2–82.2]
106.5 ± 18.69
110.7 [77.8–133.9]
136.3 ± 13.48
135.5 [120.2–159.0]
Values are presented as mean ± SD and median [range]. N◦, number; BW, body weight; BSA, body surface area; GFR, glomerular filtration rate adapted from Gasthuys et al. (2017b).
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FIGURE 2 | Mean (+ SD) desmopressin plasma concentration vs. time curves of piglets aged 8 days (n = 8), 4 weeks (n = 8), 7 weeks (n = 8), and 6 months (n = 8)
after receiving a desmopressin oral lyophilisate (120 µg).
FIGURE 3 | Graphical representation of the applied model to describe the pharmacokinetics of a desmopressin oral lyophilisate in growing piglets. D1: duration 1,
Tlag: lag time, Bio: fraction of the absorbed dose (buccal absorption), 1-Bio: fraction of the absorbed dose (assumed gastro-intestinal absorption), Ka1/Ka2: first-order
absorption rate constants, Vc (V1): apparent volume of distribution of the central compartment, VP (V2): apparent volume of distribution of the peripheral compartment,
Q: inter-compartmental flow, CL: apparent total body clearance.
AUC and T½ was observed between the 6-month-old piglets
and the other age groups. Moreover, a significant difference in
AUC and T½ was observed between the 8-day-old piglets and
the other age groups except between the T½ of the 8-day-old and
4-week-old piglets.
DISCUSSION
PK studies in the pediatric population are essential to determine
correct dosage strategies for optimal efficacy. Despite worldwide
use of desmopressin to treat nocturnal enuresis in children,
full PK studies taking growth and maturation into account
are still lacking. To date, most studies investigating the PK
of desmopressin in this population applied a sparse sampling
protocol on a limited number of patients (Osterberg et al., 2006;
De Bruyne et al., 2014). Informative animal models, such as the
conventional piglet, can be used to perform full PK studies to
provide additional information such as sampling strategies for
human pediatric clinical trials.
In the present study, a desmopressin oral lyophilisate (120µg)
was administered to growing piglets of 8 days, 4 weeks, 7 weeks,
and 6 months old. A two-compartmental pop-PK model with
absorption described by a dual input function best fitted the data.
Such a dual input function was required to describe the double
peak phenomenon in the plasma concentration-time curves. The
first input function comprises a zero-order absorption rate, most
probably related to buccal absorption of the oral lyophilisate. No
lag time was required for the first input function, indicating that
sublingual absorption occurred rapidly after oral administration
of the oral lyophilisate. The second input function comprises a
first-order absorption rate into the systemic circulation, possibly
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TABLE 2 | Population pharmacokinetic model parameter estimates after
administration of a desmopressin oral lyophilisate (120 µg) to growing piglets.
Body weight is centered on the typical weight of 10 kg.
Parameter Estimate (% shrinkage) SE RSE (%)
STRUCTURAL MODEL
CL/F = θ1 × (BW/10)θ11 × eη1 395 L/h 31.8 8.05
V1/F = θ
2 × (BW/10)θ12 × eη2 131 L 21.1 16.1
Ka1 = θ
3 × eη3 0.275 h−1 0.0272 9.89
Q/F = θ4 32 L/h 6.8 21.3
V2/F = θ
5 × eη5 436 L 137 31.4
D1 = θ
6 × eη6 0.16 h 0.0473 29.6
Ka2 = θ
7 0.399 h−1 0.0677 17.0
Bio = θ8 86% 0.0488 5.67
Tlag = θ
9 1 h 0.00196 0.20
COVARIATE MODEL
Influence of BW on CL 1.03 0.0627 6.09
Influence of BW on V1 0.691 0.135 19.54
INTER-INDIVIDUAL VARIABILITY
IIV CL/F 0.175 (1.97%) 0.0462 13.20
IIV V1/F 0.641 (25.4%) 0.264 20.59
IIV Q/F 0 (FIX) 0 0
IIV Ka1 0.0903 (16.0%) 0.0339 18.77
IIV Ka2 0 (FIX) 0 0
IIV V2/F 0.634 (61.8%) 0.202 15.93
IIV D1 0.485 (47.4%) 0.255 26.29
IIV Bio 0.627 (42.9%) 0.391 31.18
IIV Tlag 0 (FIX) 0 0
RESIDUAL ERROR
ADD = θ10 22.8% CV 0.0291 12.76
CL/F, apparent total clearance after oral administration; V/F, apparent central (V1/F)
and peripheral (V2/F) volume of distribution after oral administration; Ka1/Ka2, first-
order absorption rate constants from depot 1 and 2, respectively; Q/F, apparent
intercompartmental flow; D1, duration of the zero-order input, Bio: fraction passing
through depot 1; Tlag, lag time depot 2; BW, body weight; IIV, inter-individual variability;
ADD, additive residual error; CV, coefficient of variation; SE, standard error; RSE, residual
standard error.
related to gastro-intestinal absorption after swallowing part
of the dose. A lag time of 1 h was modeled for the second
input function, indicating that the gastro-intestinal absorption
did not start immediately after oral administration of the oral
lyophilisate. A double peak has not been observed in the plasma
concentration-time curves of a desmopressin oral lyophilisate in
pediatric clinical PK studies. Two possible explanations can be
given, first, the piglet has a different absorption of desmopressin
in comparison with humans. Second, the double peak might
be missed in the human studies due to the sparse sampling
design applied in the pediatric studies. Consequently, additional
studies with more intensive sampling in the absorption phase
are required to determine whether or not the piglet is a suitable
model to study the PK of desmopressin. This conclusion is in
accordance with the conclusions drawn by Michelet et al. (2018),
who found a significant effect of formulation (oral vs. melt)
on the IC50. This effect is physiologically implausible, since a
formulation effect is expected at the PK-side rather than the
PD-side. A possible explanation given by the authors was the
sparser sampling protocol applied in the pediatric human studies.
The absorption of desmopressin sublingual melt tablet might
appear rapidly, potentially missing a larger peak or a second peak
in the concentration-time curve. An adaption of the sampling
strategy in the pediatric clinical trials is advised with thorough
sampling during the absorption phase.
Most articles describing the PK parameters of desmopressin
administered to adults (Fjellestad-Paulsen et al., 1993; Agersø
et al., 2004; Fransén et al., 2009) applied a two- or three-
compartmental model to fit the data. Michelet et al. (2016)
combined the data collected in children by Osterberg et al.
(2006) and De Bruyne et al. (2014) and concluded that a one-
compartmental model with first-order absorption best described
the data. In the current study, a two-compartmental model was
chosen based on a smaller OFV (1OFV = 87.42) in comparison
with a one-compartmental model, despite the high values of
RSE and shrinkage for V2/F (31.4 and 61.8%, respectively). Since
our experimental design comprised a rich sampling protocol,
including a 24-h time point and younger age groups, it is possible
that these factors favor a two-compartmental model, which was
also fitted to the adult human data.
The apparent CL/F population value is 395 L/h. BW was a
significant covariate, suggesting that individuals with higher BW
have a higher absolute clearance. Since renal excretion is themain
route of elimination of desmopressin (Fjellestad-Paulsen et al.,
1993) and catabolism of desmopressin appears after active uptake
by the proximal tubules of the kidney (Maack et al., 1979), kidney
maturation might thus explain the increased clearance with
increasing BW. When including the covariate GFR, a significant
improvement of the OFV was observed, but the covariate was
not retained, since backward elimination did not reach the pre-
specified significance level. Consequently, maturation of the GFR
could only partially explain the increase in clearance. When
looking at the data, it should be noted that the apparent clearance
is presented in the current study, since the F in piglets is not
known. Therefore, the age-related difference in clearance might
also be attributable to a significant difference in F as well. Since
the F in humans is very low (<1%), this might also be the case in
piglets. Consequently, when considering the F in growing piglets,
a small difference in F could potentially lead to a significant
difference in clearance. Therefore, a follow-up study should
be performed, to determine the absolute oral bioavailability in
growing piglets. In humans, the mean population value of CL/F
after oral dosing of desmopressin in a fasted population of
children was 2330 L/h (Osterberg et al., 2006) and 2098 L/h
(Michelet et al., 2016). No significant effect of BW on CL/F could
be observed in both studies. This might be explained by the age
ranges, Osterberg et al. (2006): 6–12 years (Child), De Bruyne
et al. (2014): 5–18 years(child-adolescent), and consequently the
BW ranges included in those studies that were smaller than in
the current study (neonate-adolescent), whereby the covariate
effect of BW on clearance might be underestimated. A good
correlation can be found between the values obtained byMichelet
et al. (2016) and the values obtained by allometric scaling, namely
CL (human) = CL (pig)∗(BW human/BW pig)0.75 (ratio: 1.70),
rendering the piglet a good animal model to predict the clearance
of desmopressin in humans.
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FIGURE 4 | Diagnostic plots of the population model of desmopressin after oral lyophilisate administration to growing piglets: scatter plots of the dependent variable
(DV), namely observed plasma concentrations (Cobs), vs. the individually predicted plasma concentration values (IPRED) (A) and population predicted plasma
concentration values (PRED) (B), scatter plots of the conditional weighted residuals (CWRES) vs. time after dose (C) and PRED (D). Gray circles represent the
observed data, the full black lines are the lines of unity and the full red lines are the LOESS smoothed lines.
The apparent V1 population estimate is 131 L. As seen
with clearance, a significant covariate effect of BW was
found, suggesting that individuals with higher BW have
also an increased volume of distribution of the central
compartment. Since desmopressin has a negative clog P
(−7.711), demonstrating the hydrophilicity of this drug, the
maturational changes of the body composition could explain
the covariate effect of BW on V1 (Lawton and Witty, 2013).
However, it should be noted that the V1 is also the apparent
volume of distribution, so the age-related difference could again
be due to significant differences in F. Therefore, also here, follow-
up studies should be performed, to determine the F in growing
piglets. In humans, the mean population value of Vd/F after oral
dosing of desmopressin in a fasted population of children was
8510 L (Osterberg et al., 2006) and 8237 L (Michelet et al., 2016).
Osterberg et al. (2006) did not observe a significant effect of BW
onVd/F. However,Michelet et al. (2016) did describe a significant
effect of BW on Vd/F, suggesting that dose adjustments might
be necessary. However, Michelet et al. (2016) also stated that the
extent of the covariate effect of BW is quite unclear from the data,
since the exponent of the power relation exhibits a quite large
uncertainty. When comparing the results of Michelet et al. (2016)
and the allometric scaling of the Vd (Vd(human)=Vd (pig)
∗(BW
human/BW pig)1), the piglet is a good model to predict the Vd of
desmopressin in humans (ratio: 3.88).
The AUC and T½ in the different age groups were estimated
based on the final pop-PK model. The shrinkage for most
important primary PK parameters was acceptable, since the
shrinkage of only V2/F was higher than 30%. A significant
difference between the AUC and T½el of the different age groups
was observed. The maximum plasma concentration (Cmax) of
the 8-day-old piglets were higher and the T½el was longer in
comparison with the other age groups, which could possibly lead
to more adverse effects in this age group. When comparing these
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FIGURE 5 | Visual predictive check for the final population PK model of a
desmopressin oral lyophilisate. Gray circles represent the observed data. The
lower and upper dashed lines and solid line represent the 5th, 95th, and 50th
percentiles, respectively. The shaded areas are the 95% confidence interval of
the corresponding percentiles.
TABLE 3 | Mean (±SD) secondary PK parameter estimates after administration of
a desmopressin oral lyophilisate (120 µg) in growing piglets at 8 days, 4 weeks, 7
weeks and 6 months.
Parameter 8 days 4 weeks 7 weeks 6 months
AUC0→∞
(pg*h/mL)
1369 ± 485a,b,c 436 ± 196a,d 215 ± 94.1b,e 32.7 ± 19.1c,d,e
T½el (h) 3.83 ± 2.56
f,g 1.40 ± 0.58h 0.90 ± 0.32f,i 0.10 ± 0.04g,h,i
AUC area under the plasma concentration-time curve, T1/2el half-life. Results with the
same numerical character superscript are considered significant different (p < 0.05).
results with the results obtained by Osterberg et al. (2006) (240
µg; Cmax: ± 40 pg/mL), it can be noted that the Cmax was much
higher in the current study (120 µg; Cmax: ± 250 pg/mL). This
can be explained, since this age group was not included in the
study of Osterberg et al. (2006). The Cmax of the other age groups
included in the present study are comparable with the Cmax
obtained in the study of Osterberg et al. (2006). The desmopressin
concentrations in the 6-month-old age group are lower than the
concentrations that are required to obtain antidiuretic effects. It
is recommended that in future studies, a 240 µg oral lyophilisate
should be administered instead of a 120 µg oral lyophilisate to
the 6-month-old piglets.
CONCLUSION
The PK parameters of an oral lyophilisate of desmopressin
were successfully determined in piglets aged 8 days, 4 weeks,
7 weeks and 6 months using non-linear mixed effects modeling.
A two-compartmental model with a dual input function best
described the data, since two absorption peaks were observed
in the plasma concentration-time curves. Age related differences
could be observed in the current study. In human pediatric
trials, a one-compartmental model with first-order absorption
was fitted to the data and no double peaks were observed in
the curves, likely due to the sparse sampling strategy applied
in those studies. Therefore, it is recommended that additional
studies in children, based on the sampling protocol in the current
study, are performed to determine the PK parameters in children
based on a full documentation of the plasma concentration-time
profile
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